Mood and Proneness to Boredom Are Associated with Poorer Continuous Performance Test Results, Which May Improve with Methylphenidate Treatment, in Attention-Deficit/Hyperactivity Disorder

J Child Adolesc Psychopharmacol. 2021 May;31(4):310-314. doi: 10.1089/cap.2021.0001. Epub 2021 May 5.

Abstract

Objectives: This study aimed to evaluate the relationship between baseline test of variables of attention (TOVA) performance, attention-deficit/hyperactivity disorder (ADHD) symptom severity, mood symptoms, proneness to boredom in children with ADHD, and to assess the responses of the various scales to methylphenidate treatment. Methods: Thirty-three children and adolescents with ADHD, aged 7-18 years, were assessed at baseline with TOVA and treated for 3 months thereafter with methylphenidate. The ADHD Rating Scale (ADHD-RS), Short Boredom Proneness Scale (SBPS), Children's Depression Inventory (CDI) scale, and CDI-academic and social subscale (CDI-AS) were administered to all participants at baseline and after 3 months of methylphenidate (MPH) treatment. Results: The baseline TOVA reaction time (RT) and RT variability parameters correlated with baseline SBPS and CDI-AS scores as well as with baseline total CDI scores. Significant improvements were found in ADHD-RS, SBPS, and CDI-AS scores after MPH treatment. The alteration in ADHD-RS correlated with parallel changes in SBPS and CDI-AS scores. Conclusions: Mood and proneness to boredom correlate with poor attention-span in children with ADHD. Improvement in ADHD levels after MPH treatment correlates with a parallel decrease in mood symptoms related to academic achievement and social functioning.

Keywords: attention-deficit/hyperactivity disorder; methylphenidate; mood; proneness to boredom; test of variables of attention.

MeSH terms

  • Adolescent
  • Affect*
  • Attention / physiology*
  • Attention Deficit Disorder with Hyperactivity / drug therapy*
  • Boredom*
  • Central Nervous System Stimulants / therapeutic use*
  • Child
  • Female
  • Humans
  • Male
  • Methylphenidate / therapeutic use*
  • Psychiatric Status Rating Scales / statistics & numerical data
  • Reaction Time
  • Treatment Outcome

Substances

  • Central Nervous System Stimulants
  • Methylphenidate